Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luba Benimetskaya

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Clinical Prostate Cancer|March 30, 2004
Antisense therapy: recent advances and relevance to prostate cancerLuba Benimetskaya, C A Stein
Oligonucleotides|October 6, 2005
518A2 melanoma cells are protected by G3139 and other antineoplastic agents against the cytotoxic effects of DTICLuba Benimetskaya, Paul Miller, C A Stein
Seminars in Oncology|December 13, 2005
Antisense strategies for oncogene inactivationC A Stein, Luba Benimetskaya, S Mani
Cancer Research|April 4, 2002
Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agentsMaria Vilenchik, Anthony J Raffo, Luba Benimetskaya, et al.
Oligonucleotides|April 6, 2006
Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of actionNoah Kornblum, Kanyalakshmi Ayyanar, Luba Benimetskaya, et al.
Annals of the New York Academy of Sciences|January 6, 2006
Induction of apoptosis by G3139 in melanoma cellsLuba Benimetskaya, Johnathan C Lai, Anastasia Khvorova, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 2, 2006
A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDACJohnathan C Lai, Wenzhi Tan, Luba Benimetskaya, et al.
Molecular Cancer Therapeutics|February 17, 2005
Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cellsJohnathan C Lai, Luba Benimetskaya, Anastasia Khvorova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen)Anthony Raffo, Johnathan C Lai, C A Stein, et al.
Molecular Cancer Therapeutics|October 28, 2003
G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense mannerJonathan C Lai, Luba Benimetskaya, Regina M Santella, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Clinical Prostate Cancer|March 30, 2004
Antisense therapy: recent advances and relevance to prostate cancerLuba Benimetskaya, C A Stein
Oligonucleotides|October 6, 2005
518A2 melanoma cells are protected by G3139 and other antineoplastic agents against the cytotoxic effects of DTICLuba Benimetskaya, Paul Miller, C A Stein
Seminars in Oncology|December 13, 2005
Antisense strategies for oncogene inactivationC A Stein, Luba Benimetskaya, S Mani
Cancer Research|April 4, 2002
Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agentsMaria Vilenchik, Anthony J Raffo, Luba Benimetskaya, et al.
Oligonucleotides|April 6, 2006
Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of actionNoah Kornblum, Kanyalakshmi Ayyanar, Luba Benimetskaya, et al.
Annals of the New York Academy of Sciences|January 6, 2006
Induction of apoptosis by G3139 in melanoma cellsLuba Benimetskaya, Johnathan C Lai, Anastasia Khvorova, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 2, 2006
A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDACJohnathan C Lai, Wenzhi Tan, Luba Benimetskaya, et al.
Molecular Cancer Therapeutics|February 17, 2005
Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cellsJohnathan C Lai, Luba Benimetskaya, Anastasia Khvorova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen)Anthony Raffo, Johnathan C Lai, C A Stein, et al.
Molecular Cancer Therapeutics|October 28, 2003
G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense mannerJonathan C Lai, Luba Benimetskaya, Regina M Santella, et al.
Pageof 2